CN110251524B - 化合物党参炔苷(Lobetyolin)的制备方法及在药物中的用途 - Google Patents
化合物党参炔苷(Lobetyolin)的制备方法及在药物中的用途 Download PDFInfo
- Publication number
- CN110251524B CN110251524B CN201910571315.4A CN201910571315A CN110251524B CN 110251524 B CN110251524 B CN 110251524B CN 201910571315 A CN201910571315 A CN 201910571315A CN 110251524 B CN110251524 B CN 110251524B
- Authority
- CN
- China
- Prior art keywords
- lobetyolin
- cisplatin
- compound
- kidney injury
- acute kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title abstract description 19
- 150000001875 compounds Chemical class 0.000 title abstract description 10
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 48
- 229960004316 cisplatin Drugs 0.000 claims abstract description 47
- MMMUDYVKKPDZHS-MXFZCOKBSA-N (2R,3R,4S,5S,6R)-2-[(4E,6R,7R,12E)-1,7-dihydroxytetradeca-4,12-dien-8,10-diyn-6-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound C\C=C\C#CC#C[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)\C=C\CCCO MMMUDYVKKPDZHS-MXFZCOKBSA-N 0.000 claims abstract description 40
- MMMUDYVKKPDZHS-UHFFFAOYSA-N (4E,6R,7R,12E)-tetradeca-4,12-dien-8,10-diyne-1,6,7-triol-7-O-beta-D-glucopyranoside Natural products CC=CC#CC#CC(O)C(C=CCCCO)OC1OC(CO)C(O)C(O)C1O MMMUDYVKKPDZHS-UHFFFAOYSA-N 0.000 claims abstract description 40
- MMMUDYVKKPDZHS-JGOWZFCDSA-N Lobetyolin Natural products CC=CC#CC#C[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C=CCCCO MMMUDYVKKPDZHS-JGOWZFCDSA-N 0.000 claims abstract description 40
- DENOGTWTGDLIBH-SZMQGJMYSA-N lobetyolin Natural products CC=CC#CC#C[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C=CCCO DENOGTWTGDLIBH-SZMQGJMYSA-N 0.000 claims abstract description 40
- 241000756943 Codonopsis Species 0.000 claims abstract description 17
- 230000006907 apoptotic process Effects 0.000 claims abstract description 17
- 208000009304 Acute Kidney Injury Diseases 0.000 claims abstract description 14
- 208000033626 Renal failure acute Diseases 0.000 claims abstract description 14
- 201000011040 acute kidney failure Diseases 0.000 claims abstract description 14
- 229930182470 glycoside Natural products 0.000 claims abstract description 12
- -1 acetylenes glycoside Chemical class 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 239000008187 granular material Substances 0.000 claims abstract description 8
- 230000009467 reduction Effects 0.000 claims abstract description 7
- 239000006187 pill Substances 0.000 claims abstract description 6
- 231100000135 cytotoxicity Toxicity 0.000 claims abstract description 3
- 230000003013 cytotoxicity Effects 0.000 claims abstract description 3
- 239000007924 injection Substances 0.000 claims abstract description 3
- 238000002347 injection Methods 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 239000002552 dosage form Substances 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 58
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 230000002829 reductive effect Effects 0.000 claims description 21
- 241000007126 Codonopsis pilosula Species 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 10
- 206010061481 Renal injury Diseases 0.000 claims description 9
- 208000037806 kidney injury Diseases 0.000 claims description 9
- 241000699670 Mus sp. Species 0.000 claims description 8
- 230000036542 oxidative stress Effects 0.000 claims description 8
- 238000004440 column chromatography Methods 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- 231100000417 nephrotoxicity Toxicity 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000000287 crude extract Substances 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims description 3
- 240000003582 Platycodon grandiflorus Species 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 18
- 238000000926 separation method Methods 0.000 abstract description 9
- 210000002966 serum Anatomy 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 6
- 210000005084 renal tissue Anatomy 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 4
- 239000000843 powder Substances 0.000 abstract description 4
- 238000012404 In vitro experiment Methods 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 239000007901 soft capsule Substances 0.000 abstract description 2
- 101710170789 Protein bax Proteins 0.000 abstract 1
- 239000002778 food additive Substances 0.000 abstract 1
- 235000013373 food additive Nutrition 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 210000003292 kidney cell Anatomy 0.000 abstract 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 21
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 15
- 229940118019 malondialdehyde Drugs 0.000 description 15
- 238000000605 extraction Methods 0.000 description 10
- 229960003180 glutathione Drugs 0.000 description 10
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 241000357628 Codonopsis pilosula subsp. tangshen Species 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000005779 cell damage Effects 0.000 description 6
- 208000037887 cell injury Diseases 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 210000004926 tubular epithelial cell Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 230000003859 lipid peroxidation Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 206010029155 Nephropathy toxic Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000007694 nephrotoxicity Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000006667 mitochondrial pathway Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 101150082208 DIABLO gene Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- SMRPGWBDLOQHOS-UHFFFAOYSA-N 5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[[9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]oxane-2-carboxylic acid Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4=O)C)(C)CC3)(C)CC2)(C)CO)OC(CO)C(O)C1O SMRPGWBDLOQHOS-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 241000828608 Alyssum americanum Species 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000123667 Campanula Species 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000004046 Caspase-2 Human genes 0.000 description 1
- 108090000552 Caspase-2 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102000004039 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 229930189092 Notoginsenoside Natural products 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010060059 Sarcosine Oxidase Proteins 0.000 description 1
- 102000008118 Sarcosine oxidase Human genes 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001612 cachectic effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940105442 cisplatin injection Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000037888 epithelial cell injury Diseases 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 231100000268 induced nephrotoxicity Toxicity 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- PPRSVUXPYPBULA-UHFFFAOYSA-N saponin A Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O PPRSVUXPYPBULA-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000009211 stress pathway Effects 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了化合物党参炔苷(Lobetyolin,C20H28O8)的制备方法及在制备拮抗顺铂(CDDP)诱导的急性肾损伤药物中的应用,属于化合物制备分离及医药用途开发领域。经体内外研究表明:党参炔苷可以有效减轻顺铂导致的小鼠急性肾损伤,包括减轻小鼠血清BUN和CRE水平,减少血清中TNF‑α和IL‑1β水平,抑制肾组织中促凋亡蛋白Bax和Casapase的表达水平。经体外实验表明:党参炔苷能够减轻HEK293肾细胞活力降低和细胞毒性,提高细胞中GSH水平同时降低MDA含量。因此,可以把该化合物及含有该化合物的有效组分制备成预防急性肾损伤的药物、保健品、食品添加剂或复方制剂等。其药物或保健品可以是现有的任何剂型,如片剂,胶囊剂,粉针剂,注射剂,丸剂,软胶囊,颗粒剂和贴剂等。
Description
技术领域:
本发明涉及化合物党参炔苷(Lobetyolin)在制备预防急性肾损伤药物中的用途,属于中药化合物的制备方法及其医药用途技术领域。
背景技术:
顺铂(CDDP),全名顺式-1,2-二氯二氨合铂,是临床使用的最有效和最常见的抗肿瘤药物之一,其在有效剂量范围内广泛应用于多种骨肉瘤和实体瘤的治疗,包括卵巢癌,宫颈癌,头颈癌以及非小细胞肺癌等。然而,高剂量顺铂产生的副作用限制了其在临床中的应用。临床试验报道,顺铂常见的副作用包括肾毒性,神经毒性,耳毒性,骨髓毒性和电解质紊乱等,其中肾毒性是最常见的不良反应。研究结果显示,肾小管上皮细胞中的顺铂浓度是血液中的5倍,毒性效应主要发生在近端小管,特别是在肾小管上皮细胞的S3区段,肾小球和远端小管随后受到影响。
一般而言,顺铂诱导的肾小管损伤涉及了相互关联的因素,例如DNA损伤,线粒体功能障碍,氧化应激,炎症反应及凋亡。因此,寻找一种能够有效抑制顺铂累计所致肾毒性的药物仍是当前研究的重点。氧化应激在顺铂诱发的肾毒性的病理生理学中起着重要的作用。先前的报道显示,顺铂进入机体后,通过抑制细胞还原和清除活性氧簇(ROS)的能力,使细胞中ROS水平升高,破坏了机体内氧化和抗氧化能力的平衡,使机体发生氧化应激,最终导致机体组织器官的损伤。此外,顺铂也可能损害抗氧化剂防御机制如谷胱甘肽(GSH),超氧化物歧化酶(SOD),使它们降解或失活,从而引发氧化应激损伤。同时,顺铂在水合代谢过程中会产生大量的氧自由基可引发生物膜中多价不饱和脂肪的过氧化反应,形成脂质过氧化物MDA等,破坏膜脂质的完整性,导致肾细胞功能紊乱甚至死亡。MDA是氧自由基与生物膜不饱和脂肪酸发生脂质过氧化反应的稳定代谢产物,其含量变化能直接反映细胞内酶系统或非酶系统产生的氧自由基,触发细胞膜发生脂质过氧化损伤。
最近有关于顺铂肾毒性机制的研究聚焦于肾小管上皮细胞的凋亡,已经证实在一些凋亡途径参与了顺铂所致肾小管上皮细胞损伤,包括通过死亡受体激活的外源性途径,如肿瘤坏死因子受体或Fas途径,内源性线粒体途径及内质网应激途径。各种外界因素可以通过不同的信号传递系统传递凋亡信号,引起细胞凋亡,Fas是一种跨膜蛋白,属于肿瘤坏死因子受体超家族成员,它与FasL结合可以启动凋亡信号的转导引起细胞凋亡。此外,顺铂可激活凋亡的线粒体途径,应用顺铂处理肾小管上皮细胞,可导致Bax向线粒体移位,活化caspase-2,线粒体释放细胞色素C、凋亡诱导因子及第二个线粒体来源的胱氨酸酶激活物(SMAC/Diablo),并激活caspase-9,体内及体外试验均证实,caspase家族在顺铂致肾小管上皮细胞凋亡的执行阶段起重要作用。
综上所述,顺铂的副作用,在一定程度上限制了其在临床治疗上的应用,在天然药物中寻求有效预防急性肾损伤的成分,得到越来越多人们的普遍关注。目前,有研究报道,从中草药中获得提取物及活性成分对急性肾损伤具有一定的保护作用(参见:ZhangW.Z.et.al Platycodon grandiflorum Saponins Ameliorate Cisplatin-Induced AcuteNephrotoxicity through the NF-κB-Mediated Inflammation and PI3K/Akt/ApoptosisSignaling Pathways.Nutrients,2018;刘新文,等.三七总皂苷通过线粒体途径抑制顺铂诱导的大鼠肾细胞凋亡,中国药理学通报,2015)。
目前,大量研究表明,从中草药中获得的提取物及活性成分对急性肾损伤具有一定的保护作用。党参为桔梗科植物党参(Codonopsis pilosula(Franch.)Nannf.)的干燥根,是我国常用的一种传统补益类中药,具有调节血糖、促进造血机能、抗缺氧、抗应激、抗疲劳、增强机体免疫力、延缓衰老等多种药理作用。据报道,党参中含有皂苷、挥发油、微量生物碱蛋白质、多糖、维生素及多种氨基酸。其中党参炔苷对乙醇所致的胃黏膜损伤有很好的保护作用,与党参补益脾胃的传统功效相符,是党参保护胃黏膜的活性成分之一。此外,党参炔苷还具有较强的抗氧化活性。(参见:蒋小飞,等.党参总皂苷的提取分离和纯化[J].安徽农业科学,2011;杨亚蕾.党参炔苷与浸出物含量的相关性研究[J].中国中医药资讯,2010;M.U.Dumlu,et al,.Chemical composition and antioxidant activity ofCampanula alliariifolia.Nat Prod Res.)
到目前为止,未见有关党参炔苷对顺铂(CDDP)所致急性肾损伤保护作用的报道,本发明通过体内和体外实验创造性的提出并证明了该成分的急性肾损伤保护作用,对该化合物药用价值进行了充分的开发利用,为临床上治疗肾损伤提供了理论基础支撑。
发明内容
本发明提供了党参炔苷在制备预防顺铂(CDDP)诱导的急性肾损伤药物中的应用。
所述的党参炔苷可通过以下步骤获得:(1)取干燥的党参属样品,粉碎过200目筛,经适当的溶剂和提取方法,得到提取液,减压浓缩得浸膏;(2)用水稀释浸膏,上大孔树脂吸附柱色谱,依次用水和70%以上乙醇进行洗脱,收集醇洗脱部分,减压浓缩收集液,冷冻干燥得党参炔苷粗提物;(3)将所得样品上ODS柱,并用5%~85%甲醇的水溶液进行不同浓度洗脱,分段收集不同流出液,减压浓缩流出液,最后经重结晶,可得到纯度为95~99.99%的党参炔苷。
前述的党参属样品,可包括党参、桔梗等植物,其优选党参,提取方法可包括浸泡提取、回流提取、超声提取、超临界萃取等的任何一种;提取溶剂选自水,甲醇,乙醇任何一种及不同比例混合物;用于后续分离纯化的大孔树脂及ODS柱色谱,可包括药学上能够接受的如D101、NKA12等常规树脂及其他柱色谱。
前述的党参炔苷,主要对药源性肾损伤具有预防和治疗作用,能够在日常生活中使用,以缓解和或改善顺铂引起的肾损伤,同样该用途也可以应用到其他致病源导致的肾脏损伤。
当本发明用于上述用途时,其口服或胃肠外给药,均是安全的,在口服情况下,其可以以任何常规的形式给药,如片剂,胶囊剂,粉针剂,注射剂,丸剂,软胶囊,颗粒剂和贴剂等。
本发明制备预防和制备药源性肾损伤的党参炔苷可以与药用载体或食品载体混合,这里使用的固体或液体的赋形剂在本领域是总所周知的,下面举几个例子,散剂是内服的粉末剂,它的赋形剂有乳糖,淀粉,糊精,碳酸钙,合成或天然硫酸铝,氧化镁,硬脂酸镁,碳酸氢钠,干燥酵母等;溶液剂的赋形剂有水,甘油,1,2-丙二醇,单糖浆,乙醇,乙二醇,聚乙二醇,山梨糖醇等;软膏剂的赋形剂可以使用脂油,含水羊毛脂、凡士林、甘油、蜂蜡、木蜡、液体石蜡等组合成的疏水剂或亲水剂。
附图说明
图1:党参炔苷结构。
具体实施方式
本发明可以通过下面的实验例进一步说明。
实验例1.桔梗中党参炔苷的制备分离
制备分离过程步骤如下:(1)取干燥的桔梗根或茎叶样品,粉碎过200目筛,经甲醇或乙醇提取,得到提取液,减压浓缩得浸膏;(2)用水稀释上述浸膏,上D101大孔树脂吸附柱色谱,依次用水和70%以上乙醇进行洗脱,收集70%醇洗脱部分,减压浓缩收集液,冷冻干燥得富含党参炔苷的粗提物;(3)将所得样品过反相ODS柱,并用5%~85%甲醇的水溶液进行不同浓度洗脱,分段收集不同流出液,减压浓缩流出液,最后经重结晶,可得到纯度为95.5%的党参炔苷。
茎叶做提取试材时候优选乙醇做提取溶剂,可以有效避免叶绿素等杂质的干扰。
实验例2.轮叶党参中党参炔苷的制备分离
制备分离过程步骤如下:(1)取干燥的轮叶党参根或茎叶样品,粉碎过200目筛,经甲醇或乙醇提取,得到提取液,减压浓缩得浸膏;(2)用水稀释上述浸膏,上D101大孔树脂吸附柱色谱,依次用水和70%以上乙醇进行洗脱,收集70%醇洗脱部分,减压浓缩收集液,冷冻干燥得富含党参炔苷的粗提物;(3)将所得样品过反相ODS柱,并用5%~85%甲醇的水溶液进行不同浓度洗脱,分段收集不同流出液,减压浓缩流出液,最后经重结晶,可得到纯度为97.2%的党参炔苷。
茎叶做提取试材时候优选乙醇做提取溶剂,可以有效避免叶绿素等杂质的干扰。
实验例3.党参中党参炔苷的制备分离
制备分离过程步骤如下:(1)取干燥的党参干燥根样品,粉碎过200目筛,经甲醇或乙醇提取,得到提取液,减压浓缩得浸膏;(2)用水稀释上述浸膏,上D101大孔树脂吸附柱色谱,依次用水和70%以上乙醇进行洗脱,收集70%醇洗脱部分,减压浓缩收集液,冷冻干燥得富含党参炔苷的粗提物;(3)将所得样品过反相ODS柱,并用5%~85%甲醇的水溶液进行不同浓度洗脱,分段收集不同流出液,减压浓缩流出液,最后经重结晶,可得到纯度为96.1%的党参炔苷。
实验例4.党参炔苷对顺铂(DDDP)诱导的小鼠肾损伤的保护作用
实验方法主要参考文献(徐颀,等.毒理学杂志,2016,30,260-264),简述如下:
4.1动物分组及给药
将ICR小鼠随机分成空白对照组(Normal)、肾损伤模型组(Cisplatin)、党参炔苷低剂量给药组(10mg/kg)、党参炔苷高剂量给药组(20mg/kg)剂量组,每组10只。每天各给药组按体重10mL/Kg连续灌胃10天,每天1次,空白组和模型组均灌胃同体积生理盐水。于第7天给药后,禁食不禁水12h,肾损伤模型组和各给药组一次性腹腔注射20mg/Kg顺铂生理盐水溶液,继续给药3天,末次给药后禁食不禁水12h后眼眶静脉丛取血,离心制备血清,脱臼处死小鼠,迅速取出肾组织。将左肾置于生理盐水中制成匀浆,3000rmp/min离心5min,取上清液,试剂盒检测相关生化指标;右肾10%甲醛固定后进行病理学及免疫组织化学分析。
4.2血清中CRE,BUN及肾组织中MDA的测定
取离心后的血清,分别采用肌氨酸氧化酶法和脲酶法试剂盒测定血清中CRE和BUN水平;取肾组织匀浆上清液,采用TBA法测试盒测定MDA的含量,按照试剂盒说明书进行操作,酶标仪相应波长处比色测定OD值,计算含量。
4.3血清中TNF-α和IL-1β炎症因子的测定
采用ELISA法测定血清中炎症因子TNF-α和IL-1β的水平,根据说明书进行操作,酶标仪450nm波长处比色法测定OD值,计算含量。
4.4H&E病理组织学染色
取小鼠肾脏中部做横切面取材,常规石蜡包埋、切成5μm的切片,每组随机选取3张组织切片,进行脱蜡,梯度过酒精,苏木素(Hematoxylin)染细胞核,自来水冲洗返蓝,之后伊红(Eosin)染细胞质,常规脱水,透明,中性树胶封片,光学显微镜下观察肾小管病变。
4.5统计学方法
所有数据应用SPSS 21.0软件进行分析处理。各项数据以Mean±SD表示,P<0.01或P<0.05具有统计学意义。
结果如下(数据略):
1、与正常对照组小鼠相比,一次性顺铂注射3天后,小鼠状态萎靡,毛色灰暗,体重略有减轻,肾指数和脾指数显著升高(P<0.05),表明代谢器官受损严重,出现了免疫抑制反应;党参炔苷2个给药组,小鼠状态明显好转,体重下降得到缓解,可以明显改善顺铂所致的肾指数下降(P<0.05),改善率大于65%,但对肝和脾指数几乎不影响。
2、与模型组相比,党参炔苷2个剂量组均能不同程度的降低肾组织中MDA的含量,高剂量具有极显著性差异(P<0.01)
3、与模型组相比,党参炔苷2个剂量给药组均能够降低小鼠血清中TNF-α和IL-1β的水平,且具有显著性差异(P<0.05)。表明党参炔苷能够部分通过抑制炎症因子的表达而发挥肾保护作用。
4、与模型组相比,党参炔苷2个剂量给药组均能够降低小鼠肾组织中Bax和caspase 3的水平,且具有显著性差异(P<0.05)。表明党参炔苷能够部分通过抗凋亡作用而发挥肾保护作用。
实验例5.党参炔苷对顺铂致HEK293细胞损伤的保护作用
1材料和方法
1.1材料、试剂及仪器
党参炔苷,纯度>98.5%(HPLC);顺铂,(CDDP,纯度>99%,Pt,65%,CAS NO.15663-27-1),二甲基亚砜(DMSO)等均购自美国Sigma化学品有限公司;青霉素和链霉素各10000U/mL的DMEM培养基、胎牛血清(FBS)等均购自美国Gibco公司;3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐(MTT),北京生物技术有限公司;还原型谷胱甘肽(GSH)和丙二醛(MDA)等均购自南京建成生物工程研究所;活性氧试剂盒购自沈阳万类生物科技有限公司;Hoechst33258染色液购自上海碧云天生物技术有限公司;司;HC-2517高速离心机,安徽中科中佳科学仪器有限公司;显微镜Leica DM500,德国徕卡;SPECTRO star Nano全波长扫描式酶标仪,德国BMG LABTECH公司。
1.2HEK293细胞的培养
从ATCC细胞库获得的HEK293细胞,细胞在进行细胞培养前在液氮中保存。将HEK293细胞置于含有10%FBS以及链霉素和青霉素的DMEM培养基中,并在环境为95%空气和5%CO2的培养箱中培养。为了细胞能够良好的传代,培养基每2天更换一次。当细胞充满于培养瓶80-90%时。用1mL胰蛋白酶-EDTA溶液进行消化,已备进行下一步实验。
1.3细胞活力测试(MTT法)
使用MTT定量比色法测定细胞活力。将细胞接种到96孔板中并在37℃下培养。经过适当的培养时间后,用不同浓度的党参炔苷进行预给药,24h后,给予顺铂(20μM)进行处理,造模满24h后向每孔滴加20μL MTT溶液(5mg/mL)并在37℃下温育3.5h。然后,向每孔中滴加150μL DMSO,并在平板振荡器中振摇5min。最后,使用酶标仪(Nano,德国)在490nm处测量吸光度,产生的颜色强度与HEK 293细胞的存活数量成正比。
1.4细胞中GSH和MDA含量及活性氧(ROS)的测定
细胞中GSH含量采用二硫代对硝基苯法和钼酸铵法测定,MDA水平采用硫代巴比妥酸反应物质(TBARS)法检测,使用荧光测定法(DCFH-DA)测定细胞内活性氧的相对水平,GSH、MDA测定方法均按照试剂盒说明书进行操作,酶标仪相应波长处比色测定OD值,计算其含量。
将HEK293细胞接种到6孔板中并在37℃下培养。经过适当的培养时间后,用不同浓度的党参炔苷进行预给药。24h后,给予顺铂(20μM)进行处理,造模满24h后用10μM DCFH-DA探针在37℃,5%CO2条件下在黑暗中孵育30min。弃去培养基,用PBS洗涤细胞两次,然后在荧光显微镜(Leica TCS SP8,德国)下通过荧光强度测定产生的ROS。
1.5数据处理
2结果
2.1党参炔苷对顺铂诱导的HEK 293细胞活力降低的缓解作用
从表1可以看出,顺铂所产生的细胞毒性能够降低HEK293的细胞活力并呈剂量和时间依赖性。我们选择20μM作为模型组剂量。党参炔苷在(5-20μg/mL)的剂量以内并不影响HEK293细胞活力。与正常对照组相比,用20μM的顺铂处理后,模型组的细胞活力显著降低。而党参炔苷(5-20μg/mL)组对顺铂致药物损伤具有显著的保护作用并呈剂量依赖性,这些结果表明党参炔苷对顺铂所致的HEK293细胞活力降低具有明显改善作用,结果如下表。
表1党参炔苷对顺铂所致的HEK293细胞损伤的保护作用
2.2党参炔苷对顺铂诱导的HEK293细胞脂质过氧化的影响
从表2可以看出,与正常对照组相比,模型组细胞中GSH水平显著下降(P<0.05),而MDA水平明显升高(P<0.05),具有统计学意义,提示顺铂诱导急性肾细胞损伤模型成功建立,细胞间脂质过氧化产物累积,抗氧化代谢水平降低;与模型组相比,党参炔苷各给药剂量组细胞中的MDA含量随着给药剂量的增加而逐渐降低,并有显著性差异(P<0.05);而GSH的含量随着给予党参炔苷剂量的增加均有所提升并呈一定的剂量关系(P<0.05),表明党参炔苷可以在一定程度上缓解顺铂引起的脂质过氧化,有效改善细胞中的氧化应激损伤,结果如下表。
表2党参炔苷对顺铂致HEK 293细胞损伤中GSH和MDA水平影响
2.3党参炔苷对顺铂诱导的HEK293细胞氧化应激的影响
如表3所示,结果表明:正常HEK293细胞内存在少量的ROS,而与正常对照组相比,模型组经过20μM顺铂处理24h之后,细胞内ROS水平明显增多,而经党参炔苷给药组预处理后能明显抑制顺铂诱导的HEK293细胞氧化应激,图略。
表3党参炔苷对顺铂致HEK 293细胞损伤中ROS和凋亡的影响
2.4党参炔苷对顺铂诱导的HEK293细胞凋亡的影响
为判断党参炔苷能否减轻顺铂所引起的HEK293细胞凋亡,我们采用了Hoechst33258染色法检测了细胞的凋亡程度。如表3所示,结果表明:正常对照组相比,顺铂模型组的细胞核致密浓染,荧光强度表达较高。然而,党参炔苷给药后,与模型组比较,荧光强度明显降低且细胞核轮廓规则,以上结果表明,党参炔苷对顺铂诱导的HEK293细胞的凋亡发挥了显著地抑制作用。
3结论
党参炔苷在5~20μM剂量范围内,可以显著改善顺铂诱导的HEK293细胞活力降低和细胞损伤,主要通过改善急性氧化应激水平及抑制凋亡反应等,在一定程度上为顺铂肾毒性防护措施的研究开辟了新的思路。
实施例 药物的实施例
制备药剂的实施例一
胶囊剂的制备 100g党参炔苷,药用淀粉适量,两者充分混匀,装胶囊,制成1000粒胶囊,每粒重0.25g,每粒含党参炔苷100mg。口服,每次4粒,每日三次。
制备药剂的实施例二
片剂的制备 100g党参炔苷,药用淀粉适量,两者充分混匀,用乙醇做粘合剂制湿颗粒,干燥,过120目筛整粒,装胶囊,每粒100mg,每次口服1-2粒,每日2次。
制备药剂的实施例三
滴丸剂的制备 聚乙二醇4000 300g,在水浴上熔化,加入原料党参炔苷100g,搅拌均匀,倾入保温管中,调节恒温装置,使药液在80-90℃下滴入冷却过的液体石蜡中(温度±4℃),滴完后,将药丸倾入滤纸上吸干石蜡油,再加入少量滑石粉,混匀,得党参炔苷滴丸1000粒。口服,一次4粒,每日三次,饭后服用。
上述实施方式对本发明的党参炔苷在制备预防急性肾损伤药物方面的应用进行了简要说明,也可将党参炔苷与其他药物及活性成分组合使用,所以本发明并不局限于上述实施方式,在不脱离其要旨的范围内,可以对本发明技术方案的细节和形式进行修改或替换,在各种方式中实施本发明,其这些修改技术方案也应当在其保护范围之内,在此不再一一叙述。
Claims (4)
1.党参炔苷作为唯一活性成分在制备预防急性肾损伤药物中的应用,所述的肾损伤疾病为顺铂(CDDP)所致的急性肾损伤,表现为明显改善了顺铂所致的小鼠急性肾毒性和HEK293细胞毒性,包括抑制凋亡、减少炎症反应和氧化应激。
2.按权利要求1所述的应用,其所述的党参炔苷通过如下步骤获得:(1)取干燥的桔梗、轮叶党参或党参样品,粉碎过200目筛,经适当的溶剂和提取方法,得到提取液,减压浓缩得浸膏;(2)用水稀释浸膏,上大孔树脂吸附柱色谱,依次用水和70%以上乙醇进行洗脱,收集醇洗脱部分,减压浓缩收集液,冷冻干燥得含党参炔苷的粗提物;(3)将所得样品过ODS柱,并用5%~85%中甲醇的水溶液进行不同浓度洗脱,分段收集不同流出液,减压浓缩流出液,富集含党参炔苷样品;(4)上述样品经乙醇重结晶,得到高纯度的党参炔苷。
3.按权利要求1或2所述的应用,共特征在于:所获得的党参炔苷纯度为95~99.99%。
4.根据权利要求1或2所述的应用,其特征在于:将党参炔苷作为唯一活性成分,制成用以预防急性肾损伤的药物,制作成选自如下的剂型:片剂,胶囊剂,注射剂,丸剂,颗粒剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910571315.4A CN110251524B (zh) | 2019-06-28 | 2019-06-28 | 化合物党参炔苷(Lobetyolin)的制备方法及在药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910571315.4A CN110251524B (zh) | 2019-06-28 | 2019-06-28 | 化合物党参炔苷(Lobetyolin)的制备方法及在药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110251524A CN110251524A (zh) | 2019-09-20 |
CN110251524B true CN110251524B (zh) | 2022-07-19 |
Family
ID=67922555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910571315.4A Active CN110251524B (zh) | 2019-06-28 | 2019-06-28 | 化合物党参炔苷(Lobetyolin)的制备方法及在药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110251524B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112274521B (zh) * | 2020-11-18 | 2022-05-17 | 上海诺成药业股份有限公司 | 党参炔苷缓释微囊制剂及其制备方法 |
CN114392293A (zh) * | 2021-12-24 | 2022-04-26 | 广西中医药大学 | 轮叶党参提取物的制备方法及在防治肾脏损伤方面的应用 |
CN114931645B (zh) * | 2022-06-29 | 2024-03-22 | 广州中医药大学第一附属医院 | 抑制骨桥蛋白表达的试剂在治疗尿毒症心衰中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106074661A (zh) * | 2016-07-16 | 2016-11-09 | 吉林农业大学 | 一种轮叶党参提取物在制备预防肾损伤药物及保健品中的新用途 |
-
2019
- 2019-06-28 CN CN201910571315.4A patent/CN110251524B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106074661A (zh) * | 2016-07-16 | 2016-11-09 | 吉林农业大学 | 一种轮叶党参提取物在制备预防肾损伤药物及保健品中的新用途 |
Non-Patent Citations (3)
Title |
---|
Chemical composition and antioxidant activity of Campanula alliariifolia;M.U.Dumlu等;《Natural Product Research》;20080415;第22卷(第6期);477-482 * |
Polyacetylene glycoside attenuates ischemic kidney injury by co-inhibiting inflammation, mitochondria dysfunction and lipotoxicity;Yijie Zhou等;《Life Sciences》;20180505;第204卷;55-64 * |
蒸制轮叶党参的化学成分分析及药理活性研究;徐颀;《中国优秀博硕士学位论文全文数据库(硕士) 医药卫生科技辑》;20170215(第02期);E057-285 * |
Also Published As
Publication number | Publication date |
---|---|
CN110251524A (zh) | 2019-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9211298B2 (en) | Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses | |
CN110251524B (zh) | 化合物党参炔苷(Lobetyolin)的制备方法及在药物中的用途 | |
CN105582000B (zh) | 杜仲皮或杜仲叶中萜类物质在制备治疗老年性痴呆或阿尔茨海默病药物中的应用 | |
US20150328273A1 (en) | Extract of rehmannia glutinasa libosch for reducing blood sugar, reducing blood fat, treating leukemia, and preparation method and uses thereof | |
TWI300352B (en) | Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract | |
EP1906944A1 (en) | Schisandrin b preparation | |
KR101406138B1 (ko) | 황칠나무로부터 분리한 덴드로파녹사이드를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 조성물 | |
CN108697685A (zh) | 含有桑辛素、桑黄铜g或桑白皮的,肌肉疾病的预防及治疗用或肌功能改善用组合物 | |
US10925919B2 (en) | Agent for activating astrocyte glucose metabolism | |
BR112017005416B1 (pt) | composição farmacológica para uso em medicamento para tratar ou prevenir doenças neurológicas degenerativas contendo como ingrediente ativo extrato de mistura de casca da raiz de peônia da montanha, raiz de angelica dahurica e raiz de bupleurum ou fragmentos dos mesmos | |
Bolster et al. | Impact of selected novel plant bioactives on improvement of impaired gut barrier function using human primary cell intestinal epithelium | |
CN108463231A (zh) | 含有黃漆木提取物作为有效成分的更年期疾病的预防及治疗用组合物 | |
JP4520089B2 (ja) | ルブロフサリン配糖体含有組成物 | |
KR20160100279A (ko) | 얼레지 추출물을 포함하는 항암 조성물 | |
KR101536974B1 (ko) | 여주, 산수유, 오미자 및 대추의 혼합 추출물을 함유하는 당뇨 예방 및 개선용 조성물. | |
KR101537856B1 (ko) | 인삼 유래의 진세노사이드 Rb1의 함량이 증강된 추출 분획물을 유효성분으로 함유하는 비알코올성 지방간증의 예방 및 치료용 약제학적 조성물 | |
RU2689321C2 (ru) | Композиции и способы ингибирования синтеза триглицеридов с помощью синергетической комбинации ботанических составов | |
US20080050426A1 (en) | Method For Preparing Extract From Wild Ginseng Showing Anticancer Activity And The Composition Comprising The Same | |
KR20210039297A (ko) | 마 유래 세포외 소포체 및 이의 용도 | |
KR101385191B1 (ko) | 치커리 추출물의 근육 손상 예방, 치료 또는 개선을 위한 용도 | |
KR100529991B1 (ko) | 간염 치료제 및 예방제 또는 간보호제로 유용한 섬오갈피추출물 | |
KR20040005434A (ko) | 신경세포 보호 활성을 갖는 오디의 조추출물을 함유한조성물 | |
KR101508561B1 (ko) | 귀리를 포함하는 혼합 생약재 추출물을 함유하는 당뇨병의 예방 또는 치료용 약학조성물 | |
ES2341232T3 (es) | Extracto soluble en agua de una planta del genero solanum y procedimiento de preparacion del mismo, y composicion farmaceutica que contiene el extracto soluble en agua. | |
KR100831092B1 (ko) | 노박덩굴 추출물을 함유하는 피부 미백 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |